PROFILE |
 |
IMPATH provides the road less traveled by for doctors of cancer patients. Health care providers contract with the company, which provides patient-specific information to help diagnose cancer, recommend treatment, and predict outcomes, including specialized testing services to determine the genetic characteristics of cancer samples. IMPATH has built a database of more than 600,000 case histories and a samples archive which it is leveraging to serve managed care companies and the biopharmaceuticals industry, particularly genomics-based drug developers. IMPATH's primary clients are community hospitals lacking the facilities to perform advanced cancer diagnosis and prognosis.
COMPETITION |
 |
DIANON Systems, Inc. (DIAN)
Specialty Laboratories, Inc. (SP)
UroCor, Inc. (UCOR)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 138.20
1-Yr. Sales Growth: 61.8%
Employees: 948
Revenue per employee: $145,780.59
KEY PEOPLE |
 |
Anu D. Saad
CEO
David J. Cammarata
CFO
CONTACT INFO |
 |
521 W. 57th St., 6th Fl.
New York, NY 10019
US
Phone: 212-698-0300
Fax: 212-258-2137
Online: Web Site
|